Epoetin alfa and Darbepoetin alfa Has Maximum Share of 80% of Global Erythropoietin Drugs Market Revenue.

Erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates the mechanism of erythropoiesis (production of red blood cells). This erythropoietin (EPO) drugs are used for the treatment of chemotherapy-induced anemia; anemia is a common side-effect occurring due to chemotherapy of End Stage Renal Diseases (ESRD), cancer and HIV. Improved recombinant DNA technology has led to the development of synthetic forms of erythropoietin such as epoetin alfa, epoetin beta, darbepoetin alfa, epoetin omega, and epoetin delta among the others.

Get the Sample: https://www.alliedmarketresearch.com/request-sample/59?utm_source=openpr&utm_medium=Niranjan

Erythropoietin Drugs Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $11.9 billion by 2020, registering a CAGR of 9.7% during the period 2014 - 2020. Darbepoetin alfa is the fastest growing drug class at a CAGR of 12.9% during the forecast period, owing to its high potency and minimal side-effects.

Rising incidences of Cancer, ESRD (End Stage Renal Disease), and HIV have largely contributed to the overwhelming demand for EPO drugs. Approximately 20% of the patients suffering from Cancer/HIV and ~70% of the patients suffering from ESRD undergo chemotherapy, which induces anemia in such patients, requiring EPO treatment.

Despite this, the market has nevertheless witnesses restraints due to high priced EPO drugs resulting in minimal adoption. However, commercialization of EPO biosimilars would eventually ease the influence of restraints and fuel the market growth, primarily across the developing regions.

For Purchase Inquiry: https://www.alliedmarketresearch.com/purchase-enquiry/59?utm_source=openpr&utm_medium=Niranjan

Key findings of Erythropoietin Drugs Market:
Europe led the global EPO drug market in 2013 closely followed by North America.

Asia Pacific EPO drugs market is projected to grow at a CAGR of 13.3% during the forecast period, fastest among the four geographies.

Currently, Anemia Therapeutics (Cancer and HIV treatment) market leads the overall EPO drugs market; however, kidney therapeutic segment would emerge as the largest market segment by 2020.

Originator companies are investing in R&D for expanding product i.e. EPO drug applications to newer disorders such as neural diseases and in wound healing.

EPO drugs market is witnessing high commercialization of biosimilars for the 'off-patent' drug namely Erythropoietin alfa.

The first EPO drug - Epogen (Erythropoietin alfa), launched by Amgen, has witnessed patent expiry in 2014. Following this, a number of a biosimilar.

Erythropoietin alfa has been launched by major companies such as Biocon, Ranbaxy, Emcure Pharmaceuticals.

In addition, Amgen currently owns the patent Aranesp for Darbepoetin alfa; which is expected to expire by 2016, thus, calling for the launch of Darbepoetin Alfa biosimilars.

Some of the leading players operating in the EPO drug market are
- Amgen Inc.
- Johnson & Johnson
- Roche, LG Life Sciences Ltd.
- Biocon, Intas Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- Ranbaxy Laboratories Ltd.
- Celltrion, Inc.

About Us:-

Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact Us:-

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.